1 |
NCT02291952 |
Recruiting |
Development of Countermeasures Against Adverse Metabolic Effects of Shift Work |
|
- Behavioral: Meal schedule
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Change in plasma leptin levels across sleep/wake cycle
- Change in circadian profile of plasma leptin
- Change in glucose tolerance
- (and 8 more...)
|
22 |
All |
18 Years to 35 Years (Adult) |
NCT02291952 |
R01HL118601 |
|
November 2014 |
March 2019 |
March 2019 |
November 17, 2014 |
January 19, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
2 |
NCT02298790 |
Recruiting |
Effect of Dietary Habits on Metabolic Health |
- Overweight
- Obesity
- Prediabetes
- Meals
|
- Behavioral: Meal schedule
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Change in plasma leptin levels across sleep/wake cycle
- Change in circadian profile of plasma leptin
- Change in glucose tolerance
- (and 9 more...)
|
24 |
All |
25 Years to 55 Years (Adult) |
NCT02298790 |
R01DK099512 |
|
November 2014 |
April 2018 |
April 2018 |
November 24, 2014 |
April 24, 2017 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
3 |
NCT02617056 |
Recruiting |
Objective Assessment of Behavioral Associations of Patients With Dementia |
- Dementia
- Psychomotor Agitation
|
|
Observational |
|
- VA Office of Research and Development
- University of Massachusetts, Worcester
|
U.S. Fed / Other |
- Observational Model: Ecologic or Community
- Time Perspective: Prospective
|
- Electrodermal activity
- Association of behaviors with electrodermal activity
|
60 |
All |
Child, Adult, Senior |
NCT02617056 |
N1932-P RX001932-01 |
|
January 1, 2016 |
December 29, 2019 |
December 29, 2019 |
November 30, 2015 |
March 5, 2018 |
|
- Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
Bedford, Massachusetts, United States
|
4 |
NCT02642640 |
Recruiting |
Interaction of Melatonin and MTNR1B Genotype on Glucose Control - Study 1 |
- Glucose
- Circadian Rhythm
- Melatonin
- Genes
|
- Dietary Supplement: melatonin
- Drug: placebo
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- change in disposition index
- change in first-phase insulin release
- change in insulin sensitivity
- change in glucose tolerance
|
24 |
All |
21 Years to 55 Years (Adult) |
NCT02642640 |
2015P000857A R01DK102696 |
|
November 2016 |
June 2019 |
June 2019 |
December 30, 2015 |
March 30, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
5 |
NCT03229408 |
Not yet recruiting |
Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction |
- Polycystic Ovary Syndrome
|
- Drug: Salsalate
- Other: Placebo
|
Interventional |
Phase 2 |
- University of Illinois at Chicago
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Aim 1: Area under the curve (AUC) for circulating testosterone from serial measurements during HCG stimulation test
- Aim 2: Maximum lipid-stimulated mononuclear cell nuclear factor ĸB activation during cream challenge test
- Aim1: Whole body glucose disposal during euglycemic first phase of pancreatic clamp
- (and 2 more...)
|
90 |
Female |
18 Years to 40 Years (Adult) |
NCT03229408 |
UIC-PCOS-0617 R01DK107605-01 |
TIN-PCOS-AOD |
January 2018 |
August 31, 2021 |
August 31, 2021 |
July 25, 2017 |
October 31, 2017 |
|
|
6 |
NCT03464084 |
Recruiting |
Interaction of Melatonin With MTNR1B Genotype on Glucose Control - Study 2 |
- Glucose
- Circadian Rhythm
- Melatonin
- (and 2 more...)
|
- Drug: placebo
- Dietary Supplement: melatonin
- Other: bright light
- Other: dim light
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- change in glucose tolerance
- change in first-phase insulin release
|
24 |
All |
21 Years to 55 Years (Adult) |
NCT03464084 |
2015P000857B R01DK102696 |
|
February 17, 2018 |
May 31, 2020 |
May 31, 2020 |
March 13, 2018 |
March 30, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
7 |
NCT02214550 |
Recruiting |
Chronic Pain Risk Associated With Menstrual Period Pain |
- Cystitis, Interstitial
- Dysmenorrhea
- Migraine Disorders
- (and 4 more...)
|
|
Interventional |
Phase 4 |
- NorthShore University HealthSystem Research Institute
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Change in participant bladder pain sensitivity from baseline.
- Change in Quantitative Sensory Testing (QST) parameters regarding pelvic hyperalgesia from baseline
- Differences in EEG recorded cortical activity among participants
|
255 |
Female |
18 Years to 45 Years (Adult) |
NCT02214550 |
EH13-094 1R01DK100368-01 |
CRAMPP |
July 2014 |
September 2019 |
September 2025 |
August 12, 2014 |
February 2, 2018 |
|
- NorthShore University Health System
Evanston, Illinois, United States
|
8 |
NCT02832557 |
Recruiting |
A Salivary miRNA Diagnostic Test for Autism |
- Autism Spectrum Disorder
- Developmental Delay
|
- Other: Salivary collection
- Other: Vineland Adaptive Behavior Scale-II Assessment
- Other: Medical history questionaire
- Other: Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)
|
Observational |
|
- State University of New York - Upstate Medical University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Salivary miRNA profile
- Measures of adaptive function
- Measure of autistic behavior
|
300 |
All |
2 Years to 6 Years (Child) |
NCT02832557 |
346301 R41MH111347 |
|
November 2015 |
December 2016 |
June 2017 |
July 14, 2016 |
July 19, 2016 |
|
- SUNY Upstate Medical University
Syracuse, New York, United States
|
9 |
NCT00339287 |
Recruiting |
Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens |
- Normal Neutrophil Function
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Other
- Time Perspective: Other
|
- Neutrophil function assays.
|
200 |
All |
21 Years to 65 Years (Adult) |
NCT00339287 |
999901055 01-I-N055 |
|
February 12, 2001 |
|
|
June 21, 2006 |
March 21, 2018 |
|
- NIAID, Rocky Mountain Laboratories
Hamilton, Montana, United States
|
10 |
NCT03482986 |
Not yet recruiting New |
Role of Dietary Habits in Efficacy of Bariatric Surgery - Study C |
- Bariatric Surgery
- Sleeve Gastrectomy
- Obesity
|
- Behavioral: Dietary habits plan
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Post-intervention change in self-rated hunger
- change in caloric intake
- change in energy expenditure
- change in glucose tolerance
|
44 |
All |
22 Years to 56 Years (Adult) |
NCT03482986 |
2017P002526C R01HL140574 |
|
April 2018 |
May 2022 |
May 2022 |
March 29, 2018 |
March 29, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
11 |
NCT03470558 |
Not yet recruiting New |
Role of Dietary Habits in Efficacy of Bariatric Surgery - Study A |
- Bariatric Surgery
- Sleeve Gastrectomy
- Obesity
|
|
Observational |
|
- Brigham and Women's Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in BMI at 1-year post-surgical
|
400 |
All |
21 Years to 55 Years (Adult) |
NCT03470558 |
2017P002526A R01HL140574 |
|
April 2018 |
May 2022 |
May 2022 |
March 20, 2018 |
March 30, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
12 |
NCT02124395 |
Recruiting |
Health-related Quality of Life in Rare Kidney Stone |
- Primary Hyperoxaluria
- Cystinuria
- Adenine Phosphoribosyl Transferase Deficiency
- Dent Disease
|
- Other: Health-related Quality of Life in Rare Kidney Stone Questionnaire
|
Observational |
|
- New York University School of Medicine
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Assessment of HRQoL in patients with rare kidney stones
|
320 |
All |
5 Years and older (Child, Adult, Senior) |
NCT02124395 |
13-00968 1U54DK083908-01 |
|
August 2013 |
September 2018 |
September 2018 |
April 28, 2014 |
November 22, 2017 |
|
- Primary Hyperoxaluria and Dent Disease Registry - Mayo Clinic
Rochester, Minnesota, United States - New York University School of Medicine - Cystinuria Registry
New York, New York, United States - APRT Registry - Landspitali Universtiy Hospital
Reykjavik, Iceland
|
13 |
NCT03467906 |
Not yet recruiting |
Role of Dietary Habits in Efficacy of Bariatric Surgery - Study B |
- Bariatric Surgery
- Sleeve Gastrectomy
- Obesity
|
- Other: In-laboratory assessment
|
Observational |
|
- Brigham and Women's Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Self-rated hunger
- Self-rated appetite
- Appetite-regulating hormones
|
44 |
All |
22 Years to 56 Years (Adult) |
NCT03467906 |
2017P002526B R01HL140574 |
|
April 2018 |
May 2022 |
May 2022 |
March 16, 2018 |
March 30, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
14 |
NCT03372460 |
Recruiting |
tDCS Plus Virtual Reality for PTSD |
- Post-Traumatic Stress Disorder
|
- Device: Active stimulation
- Device: Sham stimulation
- Other: Virtual Reality (VR)
|
Interventional |
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5) Total Score
- Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)
- Psychophysiology (Skin Conductance Reactivity; SCR)
|
90 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03372460 |
D2450-R 2017-053 |
TAVRE |
April 2, 2018 |
February 1, 2022 |
March 1, 2022 |
December 13, 2017 |
April 11, 2018 |
|
- Providence VA Medical Center, Providence, RI
Providence, Rhode Island, United States
|
15 |
NCT03138603 |
Recruiting |
Metoprolol to Reduce Perioperative Myocardial Injury |
|
- Drug: Metoprolol Tartrate
- Drug: Placebo
|
Interventional |
Phase 3 |
- Washington University School of Medicine
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- myocardial injury
- MACE
- Myocardial ischemia (ST-depression/elevation duration)
- (and 7 more...)
|
600 |
All |
50 Years and older (Adult, Senior) |
NCT03138603 |
201610156 5R01HL126892 |
ORION |
December 2016 |
December 31, 2021 |
December 31, 2022 |
May 3, 2017 |
September 14, 2017 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
16 |
NCT02917629 |
Recruiting |
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment |
- Oral Cavity Neoplasm
- Oropharyngeal Neoplasm
- Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- (and 13 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet
- Other: Pharmacological Study
- Other: Placebo
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Absolute change in proliferation index (Ki-67) expression, assessed in tumor tissue by immunohistochemistry
- Change in Ki-67 expression in visually normal appearing tissue, assessed by immunohistochemistry
- Change in cleaved caspase 3 expression in visually normal appearing tissue and tumor tissue samples, assessed by immunohistochemistry
- (and 5 more...)
|
39 |
All |
18 Years and older (Adult, Senior) |
NCT02917629 |
NCI-2016-01407 N01-CN-2012-00033 UWI2016-07-01 N01CN00033 P30CA014520 |
|
August 14, 2017 |
June 10, 2019 |
June 10, 2019 |
September 28, 2016 |
March 5, 2018 |
|
- Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - University of Rochester
Rochester, New York, United States - University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
|
17 |
NCT03152864 |
Not yet recruiting |
Stabilizing Behavioral Rhythms to Improve Mental Health |
- Depressive Symptoms
- Anxiety Symptoms
- Sleep Symptoms
|
|
Interventional |
Not Applicable |
- HealthRhythms, Inc.
- National Institute of Mental Health (NIMH)
- University of Utah
|
Industry / NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- PROMIS Depression
- PROMIS Anxiety
- PROMIS Sleep
|
128 |
All |
18 Years to 65 Years (Adult) |
NCT03152864 |
1R44MH113520 R44MH113520 |
SRMH |
March 1, 2018 |
March 31, 2019 |
March 31, 2019 |
May 15, 2017 |
August 28, 2017 |
|
|
18 |
NCT02912559 |
Recruiting |
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair |
- Colon Adenocarcinoma
- DNA Repair Disorder
- Lynch Syndrome
- (and 4 more...)
|
- Drug: Atezolizumab
- Drug: Fluorouracil
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease free survival (DFS)
- Overall survival
- Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0
|
700 |
All |
18 Years and older (Adult, Senior) |
NCT02912559 |
NCI-2016-01417 A021502 U10CA180821 |
|
September 12, 2017 |
July 1, 2020 |
July 1, 2020 |
September 23, 2016 |
April 18, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 700 more...)
|
19 |
NCT01893307 |
Recruiting |
Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck |
|
- Radiation: Intensity-Modulated X-Ray Therapy (IMRT)
- Radiation: Intensity-Modulated Proton Beam Therapy (IMPT)
- Procedure: Modified barium swallow (MBS)
- Behavioral: Questionnaires
|
Interventional |
Phase 2 Phase 3 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- National Institute of Dental and Craniofacial Research (NIDCR)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rates and Severity of Late Grade 3-5 Toxicity Between Intensity-Modulated X-Ray Therapy (IMRT) and Intensity-Modulated Proton Beam Therapy (IMPT)
- Progression-Free Survival (PFS) Between Concurrent Chemo-Radiation Strategies with IMRT and IMPT Following the Treatment of Oropharyngeal Tumors
|
360 |
All |
18 Years and older (Adult, Senior) |
NCT01893307 |
2012-0825 NCI-2013-01879 R03CA188162 2U19CA021239 |
|
August 2013 |
August 2023 |
August 2023 |
July 9, 2013 |
September 20, 2017 |
|
- University of California at San Diego
La Jolla, California, United States - Florida Health Protocol Institute
West Palm Beach, Florida, United States - Northwestern Memorial Hospital
Chicago, Illinois, United States - (and 7 more...)
|
20 |
NCT02185417 |
Recruiting |
Diuretic Comparison Project |
|
- Drug: Hydrochlorothiazide (HCTZ)
- Drug: Chlorthalidone
|
Interventional |
Phase 3 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to major cardiovascular event
- Time to event for each component of the composite primary outcome and additional cardiovascular events
- All Deaths
- (and 8 more...)
|
13500 |
All |
65 Years and older (Adult, Senior) |
NCT02185417 |
597 |
DCP |
June 15, 2016 |
October 15, 2022 |
April 15, 2023 |
July 9, 2014 |
January 12, 2018 |
|
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California, United States - VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts, United States - Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, United States - (and 2 more...)
|
21 |
NCT03206060 |
Recruiting |
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma |
- Pheochromocytoma
- Paraganglioma
- Neuroendocrine Tumors
- Neuroendocrine Neoplasms
|
- Drug: Lu-177-DOTATATE
- Drug: Ga-68-DOTATATE
- Other: F-18-FDG
- Drug: Amino Acid solution
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival
- safety and tolerability profile
- Determine ability to decrease anti-hypertensive medication
- (and 5 more...)
|
90 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT03206060 |
170087 17-C-0087 |
|
October 10, 2017 |
January 1, 2022 |
January 1, 2024 |
July 2, 2017 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
22 |
NCT03442296 |
Not yet recruiting |
Baltimore HEARS: Hearing Equality Through Accessible Research & Solutions |
- Age-related Hearing Impairment 1
- Personal Communication
|
- Behavioral: Baltimore HEARS
- Device: Baltimore HEARS
|
Interventional |
Not Applicable |
- Johns Hopkins University
- National Institute on Deafness and Other Communication Disorders (NIDCD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- 10 Item Hearing Handicap Inventory for the Elderly Screening (HHIE-S)
- Changes in Self-reported Loneliness
- Change in Self-reported Depression
|
100 |
All |
60 Years to 100 Years (Adult, Senior) |
NCT03442296 |
IRB00144968 |
HEARS |
April 2, 2018 |
December 31, 2019 |
July 31, 2020 |
February 22, 2018 |
February 22, 2018 |
|
- Catholic Charities
Baltimore, Maryland, United States - Weinberg Senior Living Communities
Baltimore, Maryland, United States
|
23 |
NCT03409276 |
Recruiting |
Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults |
|
- Biological: env (A,B,C,A/E)/gag (C) DNA Vaccine
- Biological: gp120 (A,B,C,A/E) Protein Vaccine
- Biological: Placebo
- Biological: GLA-SE adjuvant
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Frequency of local injection site (including DTH) reactogenicity signs and symptoms
- Frequency of systemic reactogenicity signs and symptoms
- Frequency of adverse events (AEs)
- (and 8 more...)
|
60 |
All |
18 Years to 50 Years (Adult) |
NCT03409276 |
HVTN 124 38302 |
|
March 16, 2018 |
February 2020 |
October 2020 |
January 24, 2018 |
March 27, 2018 |
|
- Case Clinical Research Site
Cleveland, Ohio, United States - Penn Prevention CRS
Philadelphia, Pennsylvania, United States
|
24 |
NCT01269164 |
Recruiting |
Face Transplantation Clinical Trial |
- Severe Facial Deformities
|
- Procedure: Surgical Procedure Composite Facial Transplant
|
Interventional |
Not Applicable |
- The Cleveland Clinic
- United States Department of Defense
|
Other / U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the success of the face transplant
- Evaluate tolerogenic properties of the immunosuppression protocol
|
2 |
All |
18 Years to 60 Years (Adult) |
NCT01269164 |
IRB6914 |
|
July 2010 |
March 2022 |
December 2022 |
January 4, 2011 |
May 31, 2017 |
|
- Cleveland Clinic
Cleveland, Ohio, United States
|
25 |
NCT02432560 |
Recruiting |
Safety and Durability of Sirolimus for Treatment of LAM |
|
- Drug: Sirolimus
- Drug: Everolimus
|
Observational |
|
- University of Cincinnati
- Rare Diseases Clinical Research Network
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety (subjects will collect symptoms in diary)
- Efficacy - FEV1 slope
- Efficacy -10% reduction in FEV1
- (and 4 more...)
|
300 |
Female |
18 Years and older (Adult, Senior) |
NCT02432560 |
MIDAS 1U54HL127672 |
MIDAS |
March 2015 |
April 2019 |
April 2020 |
May 4, 2015 |
April 11, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Stanford University Medical Center
Stanford, California, United States - National Jewish Health
Denver, Colorado, United States - (and 20 more...)
|
26 |
NCT02298231 |
Recruiting |
Improving Balance in TBI Using Virtual Reality |
|
- Other: Standard of Care Balance Intervention
- Other: Mystic Isle Balance Intervention
- Other: Mystic Isle Balance Intervention with Dual Task
|
Interventional |
Not Applicable |
- Kessler Foundation
- Fort Belvoir Community Hospital
- University of Southern California
- (and 2 more...)
|
Other / U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Balance Assessment
- Global Functioning evaluating the impact of the intervention on everyday life
- Neuropsychological Assessment examining changes in cognitive functioning
|
180 |
All |
18 Years to 65 Years (Adult) |
NCT02298231 |
R-831-14 |
|
April 2016 |
October 2018 |
October 2018 |
November 21, 2014 |
October 14, 2016 |
|
- Kessler Foundation
West Orange, New Jersey, United States
|
27 |
NCT03224000 |
Recruiting |
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer |
- Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Oropharyngeal Cancer
|
- Procedure: Modified Barium Swallow (MBS)
- Behavioral: Swallowing Questionnaire
- Behavioral: Symptom Questionnaire
- (and 4 more...)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Locoregional Control
- Composite Dysphagia Outcome Determined by PEG Tube Dependence at Last Follow-Up
- Composite Dysphagia Outcome Determined by Trace or Frank Aspiration Seen on Modified Barium Swallow Study
- (and 13 more...)
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT03224000 |
2015-0851 |
|
January 17, 2018 |
January 2025 |
January 2026 |
July 21, 2017 |
January 23, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
28 |
NCT02997319 |
Recruiting |
Shift Work, Heredity, Insulin, and Food Timing Study |
- Shift Work Type Circadian Rhythm Sleep Disorder
- Diabetes Mellitus, Type 2
- Circadian Rhythm Sleep Disorder, Shift Work Type
- Insulin Resistance
|
|
Observational |
|
- Massachusetts General Hospital
- Broad Institute
- Brigham and Women's Hospital
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Area Under the Curve (AUC) glucose
- Disposition index
- Corrected Insulin Response
- (and 4 more...)
|
1000 |
All |
18 Years to 60 Years (Adult) |
NCT02997319 |
2016P000651 R01DK105072 |
SHIFT |
January 2017 |
July 2020 |
June 2021 |
December 20, 2016 |
April 17, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
29 |
NCT03354975 |
Recruiting |
Experiential Training for Community Therapists |
|
- Behavioral: Experiential Training
- Behavioral: Training-As-Usual
|
Interventional |
Not Applicable |
- Temple University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change from baseline Therapist Beliefs about Exposure Scale (TBES) at 3-month follow-up
- Change from baseline Exposure Therapy Clinical Use Survey (ETCUS) at 3-month follow-up
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03354975 |
260359 F31MH112211 |
|
March 23, 2018 |
July 1, 2018 |
November 1, 2018 |
November 28, 2017 |
March 27, 2018 |
|
- Temple University
Philadelphia, Pennsylvania, United States
|
30 |
NCT00074568 |
Recruiting |
Scleroderma Registry |
- Systemic Sclerosis
- Scleroderma
|
|
Observational |
|
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- The University of Texas Health Science Center, Houston
|
NIH / Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Establish National registry of Scleroderma as resource for scleroderma scientific community
|
5000 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00074568 |
NIAMS-108 N01AR02251-000 NO1-AR-0-2251 |
Registry |
September 2000 |
January 2022 |
|
December 17, 2003 |
January 6, 2016 |
|
- University of Texas - Houston Medical School
Houston, Texas, United States
|
31 |
NCT02817074 |
Recruiting |
MIND Diet Intervention and Cognitive Decline |
- Cognitive Decline
- Dementia
- Alzheimer Disease
- Vascular Dementia
|
- Behavioral: MIND Diet
- Behavioral: Mild Weight Loss
|
Interventional |
Phase 3 |
- Rush University Medical Center
- Harvard School of Public Health
- Brigham and Women's Hospital
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in global cognitive score
- Change in brain MRI total brain /intracranial volume (cubic centimeters) and hippocampal/intracranial volume (cubic centimeters)
|
600 |
All |
65 Years to 84 Years (Adult, Senior) |
NCT02817074 |
R01 AG051641 1R01AG052583-01 |
MIND |
January 2017 |
December 2020 |
March 2021 |
June 29, 2016 |
April 13, 2018 |
|
- Rush University
Chicago, Illinois, United States - Harvard School of Public Health
Boston, Massachusetts, United States
|
32 |
NCT02988388 |
Recruiting |
Lung Tissue Research Consortium |
- Chronic Obstructive Pulmonary Disease
- Interstitial Lung Disease
|
- Procedure: Lung biopsy/lobectomy
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
|
400 |
All |
21 Years and older (Adult, Senior) |
NCT02988388 |
LTR01 |
LTRC |
February 23, 2017 |
March 2019 |
March 2019 |
December 9, 2016 |
August 10, 2017 |
|
- University of Michigan
Ann Arbor, Michigan, United States - Mayo Clinic Rochester
Rochester, Minnesota, United States - Temple University
Philadelphia, Pennsylvania, United States - University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
33 |
NCT01184547 |
Recruiting |
Effects of a Community Based Exercise Program in Adults With Severe Burns |
- Burn Injury
- Psychosocial Problem
- Quality of Life
|
- Behavioral: Quality of Life questionaires
|
Interventional |
Not Applicable |
- The University of Texas Medical Branch, Galveston
- United States Department of Defense
- American Burn Association
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Quality of Life/Return to Work
- Peak aerobic capacity
- Peak Aerobic Capacity
|
60 |
All |
18 Years to 60 Years (Adult) |
NCT01184547 |
10-034 A-15774.3a |
COMBEX |
April 2010 |
December 2017 |
December 2018 |
August 19, 2010 |
July 11, 2017 |
|
- University of Texas Medical Branch
Galveston, Texas, United States
|
34 |
NCT03208179 |
Not yet recruiting |
Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa |
- Pregnancy
- Malaria in Pregnancy
- Malaria
|
- Drug: dihydroartemisinin-piperaquine
- Drug: sulphadoxine-pyrimethamine
- Drug: dihydroartemisinin-piperaquine plus azithromycin
|
Interventional |
Phase 3 |
- Liverpool School of Tropical Medicine
- College of Medicine, University of Malawi
- Kenya Medical Research Institute
- (and 16 more...)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Adverse pregnancy outcome
- Composite of foetal loss and neonatal mortality
- SGA-LBW-PT composite
- (and 25 more...)
|
4680 |
Female |
Child, Adult, Senior |
NCT03208179 |
16.049 |
IMPROVE |
September 2017 |
August 2019 |
October 2019 |
July 5, 2017 |
July 5, 2017 |
|
- Ahero Sud-countyHospital
Ahero, Kisumu, Kenya - Homa Bay County Hospital
Homa Bay, Kenya - Rabour Sub-county Hospital
Kisumu, Kenya - (and 4 more...)
|
35 |
NCT03274687 |
Recruiting |
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer |
- Prostate Adenocarcinoma
- Stage I Prostate Adenocarcinoma
- Stage II Prostate Adenocarcinoma
- Stage III Prostate Adenocarcinoma
|
- Radiation: Hypofractionated Radiation Therapy
- Other: Laboratory Biomarker Analysis
- Other: Quality-of-Life Assessment
- Radiation: Radiation Therapy
|
Interventional |
Not Applicable |
- NRG Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in score for the GI domain of the EPIC
- Change in score for the total GU domain (combined urinary incontinence and urinary irritative/obstructive scales) of the EPIC
- Distant Metastasis (DM) defined as radiographic evidence of hematogenous spread evaluated by bone scan, CT, or MRI
- (and 9 more...)
|
282 |
Male |
18 Years and older (Adult, Senior) |
NCT03274687 |
NRG-GU003 NCI-2016-01771 U10CA180868 |
|
July 28, 2017 |
July 15, 2021 |
July 31, 2026 |
September 7, 2017 |
December 27, 2017 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Marin Cancer Care Inc
Greenbrae, California, United States - (and 150 more...)
|
36 |
NCT00632853 |
Recruiting |
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide |
|
- Radiation: Standard Radiation Dose Therapy
- Drug: cisplatin
- Drug: etoposide
- (and 2 more...)
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival time between 3 treatment arms
- Complete and partial response rates
- Failure-free survival
|
729 |
All |
18 Years and older (Adult, Senior) |
NCT00632853 |
CALGB-30610 RTOG 0538 U10CA031946 CDR0000588879 NCI-2009-00470 |
|
March 2008 |
June 2023 |
|
March 11, 2008 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - The Kirklin Clinic at Acton Road
Birmingham, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - (and 897 more...)
|
37 |
NCT03367702 |
Recruiting |
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer |
- Stage II Prostate Adenocarcinoma
|
- Radiation: Intensity-Modulated Radiation Therapy (IMRT)
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
|
Interventional |
Phase 3 |
- NRG Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Patients-Reported Gastrointestinal and Genitourinary Toxicity
- Disease Free Survival
- Biochemical Failure
- (and 8 more...)
|
606 |
Male |
18 Years and older (Adult, Senior) |
NCT03367702 |
NRG-GU005 NCI-2017-01398 U10CA180868 |
|
November 16, 2017 |
December 31, 2023 |
December 31, 2028 |
December 11, 2017 |
February 21, 2018 |
|
- Arizona Center for Cancer Care-Peoria
Peoria, Arizona, United States - Arizona Breast Cancer Specialists-Scottsdale
Scottsdale, Arizona, United States - Decatur Memorial Hospital
Decatur, Illinois, United States - (and 16 more...)
|
38 |
NCT03070886 |
Recruiting |
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery |
- Stage I Prostate Adenocarcinoma
- Stage II Prostate Adenocarcinoma
- Stage III Prostate Adenocarcinoma
|
- Drug: Bicalutamide
- Drug: Docetaxel
- Radiation: External Beam Radiation Therapy
- (and 5 more...)
|
Interventional |
Phase 2 Phase 3 |
- NRG Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Freedom from progression (FFP) (Phase II)
- Metastasis free survival (MFS) (Phase III)
- Overall survival
- (and 3 more...)
|
612 |
Male |
18 Years and older (Adult, Senior) |
NCT03070886 |
NRG-GU002 NCI-2016-00963 U10CA180868 |
|
January 16, 2017 |
May 2026 |
May 2031 |
March 6, 2017 |
December 27, 2017 |
|
- Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona, United States - The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States - (and 183 more...)
|
39 |
NCT02364557 |
Recruiting |
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer |
- Dyspnea
- Fatigue
- Nausea and Vomiting
- (and 2 more...)
|
- Radiation: Stereotactic Radiosurgery
- Procedure: Therapeutic Conventional Surgery
- Other: Laboratory Biomarker Analysis
|
Interventional |
Not Applicable |
- NRG Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (failure: progression or death due to any cause) (Phase II-R)
- Overall survival (failure: death due to any cause) (Phase III)
- Appearance of new metastases
- (and 5 more...)
|
402 |
All |
18 Years and older (Adult, Senior) |
NCT02364557 |
NRG-BR002 NCI-2014-01810 U10CA180868 |
|
December 2014 |
December 2022 |
December 2027 |
February 18, 2015 |
January 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Arizona Center for Cancer Care-Peoria
Peoria, Arizona, United States - University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona, United States - (and 111 more...)
|
40 |
NCT02927249 |
Recruiting |
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy |
- Node Positive HER2 Negative Breast Cancer
|
- Other: Placebo
- Drug: Aspirin
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- United States Department of Defense
- Bayer
|
Other / NIH / U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Invasive disease-free survival (iDFS)
- Overall survival (OS)
- Distant disease free survival (DDFS)
- (and 2 more...)
|
2936 |
All |
18 Years to 69 Years (Adult, Senior) |
NCT02927249 |
A011502 NCI-2016-00233 U10CA180821-01 |
|
December 2016 |
April 2021 |
|
October 7, 2016 |
April 9, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1176 more...)
|
41 |
NCT02166463 |
Recruiting |
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma |
- Ann Arbor Stage IIB Hodgkin Lymphoma
- Ann Arbor Stage IIIB Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- (and 4 more...)
|
- Biological: Bleomycin Sulfate
- Drug: Brentuximab Vedotin
- Drug: Cyclophosphamide
- (and 8 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Event free survival (EFS), where events include disease progression or relapse, second malignancy, or death
- Proportion of patients with early response defined as no slow responding lesions (SRL) and no progressive disease (PD) at all sites determined by positron emission tomography (PET) per Deauville criteria through central review
- Proportion of patients needing protocol-directed radiation therapy (RT) defined as patients with slow responding lesions (SRL) or progressive disease (PD)
- Proportion of patients experiencing grade 3+ peripheral neuropathy assessed by modified Balis scale
|
600 |
All |
2 Years to 22 Years (Child, Adult) |
NCT02166463 |
NCI-2014-01223 s15-00950 AHOD1331 U10CA180886 |
|
March 16, 2015 |
November 30, 2019 |
November 30, 2019 |
June 18, 2014 |
April 12, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - (and 188 more...)
|
42 |
NCT02133183 |
Recruiting |
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma |
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Sapanisertib
- Procedure: Therapeutic Conventional Surgery
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who achieve a drug concentration >= 70 nM in contrast enhancing tumor tissue
- Difference in ratio of the S6 phosphorylation over the total between the two groups
- Difference of the pS6 concentration between the two groups
- (and 8 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02133183 |
NCI-2014-00907 ABTC-1301 1301 U01CA137443 UM1CA137443 |
|
May 12, 2014 |
December 31, 2018 |
|
May 7, 2014 |
April 10, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - UCSF Medical Center-Parnassus
San Francisco, California, United States - (and 7 more...)
|
43 |
NCT02101905 |
Recruiting |
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma |
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Anaplastic Oligodendroglioma
- (and 4 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Lapatinib Ditosylate
- Other: Pharmacological Study
- Procedure: Therapeutic Conventional Surgery
|
Interventional |
Not Applicable |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Lapatinib ditosylate intratumoral concentration (pharmacokinetics)
- Ratio of phosphorylated (p)EGFR/total EGFR (PD) in tumor tissue
- Incidence of adverse events (AEs)
- (and 5 more...)
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT02101905 |
NCI-2014-00634 ABTC-1302 U01CA137443 UM1CA137443 |
|
March 13, 2014 |
June 30, 2018 |
|
April 2, 2014 |
April 13, 2018 |
|
- UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - (and 9 more...)
|
44 |
NCT01013649 |
Recruiting |
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery |
- Pancreatic Acinar Cell Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Intraductal Papillary-Mucinous Neoplasm
- (and 4 more...)
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Capecitabine
- Drug: Chemotherapy
- (and 6 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (Phase II)
- Overall survival (Phase III)
- Disease-free survival
- (and 3 more...)
|
950 |
All |
18 Years and older (Adult, Senior) |
NCT01013649 |
NCI-2011-01987 RTOG 0848 11-00773 CDR0000659092 RTOG-0848 U10CA180830 U10CA180868 U10CA021661 |
|
November 17, 2009 |
August 31, 2020 |
|
November 16, 2009 |
April 17, 2018 |
|
- Providence Hospital
Mobile, Alabama, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 702 more...)
|
45 |
NCT01872975 |
Recruiting |
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery |
- Stage IB Breast Cancer
- Stage II Breast Cancer
|
- Radiation: regional nodal XRT
- Radiation: chestwall XRT
- Radiation: WBI
|
Interventional |
Not Applicable |
- NSABP Foundation Inc
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- IBC-RFI
- OS
- LRRFI
- (and 6 more...)
|
1636 |
Female |
18 Years and older (Adult, Senior) |
NCT01872975 |
NSABP-B-51 NCI-2012-03198 U10CA012027 |
|
August 2013 |
July 2023 |
August 2028 |
June 7, 2013 |
May 16, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 518 more...)
|
46 |
NCT03479203 |
Not yet recruiting New |
Acute Effects of E-Cigarette Aerosol Inhalation |
- Endothelial Dysfunction
- Biochemical Markers
|
- Drug: Electronic Cigarette Aerosol
|
Interventional |
Early Phase 1 |
- University of Pennsylvania
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Changes in serum protein levels (micrograms) of inflammatory biomarkers (HMGB-1, RAGE, ICAM, CRP) in non-smoking healthy subjects before and after electronic cigarette aerosol inhalation.
- Aortic pulse-wave velocity (meters/second)
- Femoral artery flow-mediated dilation (% fractional change in cross-sectional area)
- (and 4 more...)
|
39 |
All |
18 Years to 35 Years (Adult) |
NCT03479203 |
828195 R01HL139358 |
|
March 2018 |
February 2020 |
February 2021 |
March 27, 2018 |
March 27, 2018 |
|
- University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania, United States
|
47 |
NCT01503086 |
Recruiting |
Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy |
- Childhood Brain Tumor
- Cognitive/Functional Effects
- Neurotoxicity
- (and 2 more...)
|
- Other: computer-assisted cognitive training
- Other: questionnaire administration
- Procedure: cognitive assessment
- (and 2 more...)
|
Interventional |
Not Applicable |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Intervention compliance defined as at least 80% of sessions completed (i.e., completing at least 20 sessions within 9 weeks of starting training)
- Parent-rated executive function and WM using the Metacognition subscales from the Behavior Rating Inventory of Executive Function (BRIEF)
- Executive function using the Groton Maze Learning and Set Shifting tasks of the CogState battery
- (and 5 more...)
|
71 |
All |
6 Years to 16 Years (Child) |
NCT01503086 |
ACCL10P1 NCI-2012-00112 CDR0000721387 COG-ACCL10P1 U10CA095861 |
|
November 2013 |
April 2018 |
April 2018 |
January 2, 2012 |
July 12, 2017 |
|
- Children's Oncology Group
Arcadia, California, United States - Children's National Medical Center
Washington, D.C., District of Columbia, United States - Washington University School of Medicine
Saint Louis, Missouri, United States - (and 6 more...)
|
48 |
NCT00898365 |
Recruiting |
Study of Kidney Tumors in Younger Patients |
- Clear Cell Sarcoma of the Kidney
- Congenital Mesoblastic Nephroma
- Diffuse Hyperplastic Perilobar Nephroblastomatosis
- (and 10 more...)
|
- Other: laboratory biomarker analysis
- Other: cytology specimen collection procedure
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Disease-free survival
- Overall survival
- Loss of heterozygosity (LOH testing discontinued as of April 2014)
|
5000 |
All |
up to 29 Years (Child, Adult) |
NCT00898365 |
AREN03B2 NCI-2009-00416 COG-AREN03B2 U10CA180886 U10CA098543 |
|
February 2006 |
January 2100 |
January 2100 |
May 12, 2009 |
November 29, 2017 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - (and 228 more...)
|
49 |
NCT02244814 |
Recruiting |
Trial of Diet in Gestational Diabetes Mellitus: Metabolic Consequences to Mother and Offspring |
- Gestational Diabetes Mellitus
|
- Behavioral: Low Carbohydrate/Conventional
- Behavioral: Choosing Healthy Options in Carbohydrate Energy
|
Interventional |
Not Applicable |
- University of Colorado, Denver
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Neonatal adiposity
- Maternal Insulin Resistance
- Placental fatty acid transporter protein-2 expression
|
148 |
All |
up to 36 Years (Child, Adult) |
NCT02244814 |
14-1358 |
CHOICE |
April 2015 |
June 2019 |
December 2019 |
September 19, 2014 |
December 7, 2016 |
|
- University of Colorado/Anschutz Medical Campus
Aurora, Colorado, United States
|
50 |
NCT02750826 |
Recruiting |
Breast Cancer WEight Loss Study (BWEL Study) |
|
- Other: Health Education Program
- Other: Weight Loss Intervention
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Division of Cancer Control
- NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive disease-free survival
- Overall survival
- Distant disease-free survival
- (and 20 more...)
|
3136 |
Female |
18 Years and older (Adult, Senior) |
NCT02750826 |
A011401 NCI-2015-01918 |
|
August 2016 |
May 2030 |
|
April 26, 2016 |
April 9, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 1259 more...)
|